This month’s announcements of awards, expansions, name changes, hires, and other news includes items from CPhI, Almac Group, ICON, and other organizations.
The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.
A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
This month’s launches, expanded facilities, partnerships, and other news includes items from Veeva, Hovione, Florence, Medidata, and other notable firms.
During our November 17 webinar Patient-centric solutions, a group of professionals representing a range of perspectives will share ideas and innovations.
The group is collaborating with AbbVie, Janssen, Novartis, Pfizer, and UCB to help advance nocturnal scratch as a digital endpoint for atopic dermatitis.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
A leader from the language and tech solutions firm explains how multilingual support can improve patient recruitment and other aspects of clinical trials.
The radvocacy group is joining with the Rare Disease Diversity Coalition on an initiative to identify and overcome challenges faced by minority patients.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.
